The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 08, 2022
Filed:
Nov. 04, 2016
Applicant:
Hookipa Biotech Gmbh, Vienna, AT;
Inventors:
Assignee:
Hookipa Biotech GmbH, Vienna, AT;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 39/00111 (2018.08); A61K 39/00116 (2018.08); A61K 39/00117 (2018.08); A61K 39/00118 (2018.08); A61K 39/00119 (2018.08); A61K 39/001103 (2018.08); A61K 39/001104 (2018.08); A61K 39/001106 (2018.08); A61K 39/001108 (2018.08); A61K 39/001109 (2018.08); A61K 39/001112 (2018.08); A61K 39/001113 (2018.08); A61K 39/001117 (2018.08); A61K 39/001122 (2018.08); A61K 39/001124 (2018.08); A61K 39/001126 (2018.08); A61K 39/001135 (2018.08); A61K 39/001138 (2018.08); A61K 39/001139 (2018.08); A61K 39/001149 (2018.08); A61K 39/001151 (2018.08); A61K 39/001152 (2018.08); A61K 39/001153 (2018.08); A61K 39/001156 (2018.08); A61K 39/001157 (2018.08); A61K 39/001159 (2018.08); A61K 39/001162 (2018.08); A61K 39/001164 (2018.08); A61K 39/001166 (2018.08); A61K 39/001168 (2018.08); A61K 39/001171 (2018.08); A61K 39/001172 (2018.08); A61K 39/001174 (2018.08); A61K 39/001176 (2018.08); A61K 39/001182 (2018.08); A61K 39/001184 (2018.08); A61K 39/001186 (2018.08); A61K 39/001188 (2018.08); A61K 39/001189 (2018.08); A61K 39/001191 (2018.08); A61K 39/001192 (2018.08); A61K 39/001193 (2018.08); A61K 39/001194 (2018.08); A61K 39/001195 (2018.08); A61K 39/001197 (2018.08); A61K 39/12 (2013.01); A61P 35/00 (2018.01); C12N 15/62 (2013.01); A61K 2039/5256 (2013.01);
Abstract
The present application relates generally to genetically modified arenaviruses that are suitable vaccines against neoplastic diseases, such as cancer. The arenaviruses described herein may be suitable for vaccines and/or treatment of neoplastic diseases and/or for the use in immunotherapies. In particular, provided herein are methods and compositions for treating a neoplastic disease by administering a genetically modified arenavirus in combination with an immune checkpoint inhibitor, wherein the arenavirus has been engineered to include a nucleotide sequence encoding a tumor antigen, tumor associated antigen or antigenic fragment thereof.